Perrigo Company plc Deferred Income Tax Liabilities, Net
Perrigo Company plc (PRGO) had Deferred Income Tax Liabilities, Net of $146.70 million as of 2026-06-27, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:DeferredIncomeTaxLiabilitiesNet · last filed 2026-08-05
- 2026-06-27: Deferred Income Tax Liabilities, Net $146.70M.
- 2026-03-28: Deferred Income Tax Liabilities, Net $153.50M.
- 2025-12-31: Deferred Income Tax Liabilities, Net $168.90M.
- 2025-09-27: Deferred Income Tax Liabilities, Net $194.40M.
| Period end | Deferred Income Tax Liabilities, Net | Deferred Income Tax Liabilities, Net as first filed |
|---|---|---|
| 2026-06-27 | $146.70M 10-Q · filed 2026-08-05 | |
| 2026-03-28 | $153.50M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $168.90M 10-Q · filed 2026-08-05 | |
| 2025-09-27 | $194.40M 10-Q · filed 2025-11-05 | |
| 2025-06-28 | $206.80M 10-Q · filed 2025-08-06 | |
| 2025-03-29 | $189.20M 10-Q · filed 2025-05-07 | |
| 2024-12-31 | $203.20M 10-K · filed 2026-02-26 | |
| 2024-09-28 | $213.80M 10-Q · filed 2024-11-06 | |
| 2024-06-29 | $211.70M 10-Q · filed 2024-08-02 | |
| 2024-03-30 | $247.70M 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $262.30M 10-K · filed 2025-02-28 | |
| 2023-09-30 | $349.40M 10-Q · filed 2023-11-07 | |
| 2023-07-01 | $344.60M 10-Q · filed 2023-08-08 | |
| 2023-04-01 | $333.80M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $368.20M 10-K · filed 2024-02-27 | |
| 2022-10-01 | $409.10M 10-Q · filed 2022-11-08 | |
| 2022-07-02 | $392.10M 10-Q · filed 2022-08-09 | |
| 2022-04-02 | $238.90M 10-Q · filed 2022-05-11 | |
| 2021-12-31 | $239.30M 10-K · filed 2023-02-28 | |
| 2021-10-02 | $243.00M 10-Q · filed 2021-11-12 | |
| 2021-07-03 | $254.90M 10-Q · filed 2021-08-11 | |
| 2021-04-03 | $261.40M 10-Q · filed 2021-05-12 | |
| 2020-12-31 | $276.20M 10-K · filed 2022-03-01 | $279.30M 10-K · filed 2021-03-01 |
| 2020-09-26 | $313.50M 10-Q · filed 2020-11-05 | |
| 2020-06-27 | $291.60M 10-Q · filed 2020-08-05 | |
| 2020-03-28 | $286.30M 10-Q · filed 2020-05-05 | |
| 2019-12-31 | $280.60M 10-K · filed 2021-03-01 | |
| 2019-09-28 | $314.30M 10-Q · filed 2019-11-06 | |
| 2019-06-29 | $280.20M 10-Q · filed 2019-08-08 | |
| 2019-03-30 | $282.40M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $282.30M 10-K · filed 2020-02-27 | |
| 2018-09-29 | $294.70M 10-Q · filed 2018-11-08 | |
| 2018-06-30 | $290.80M 10-Q · filed 2018-08-09 | |
| 2018-03-31 | $332.00M 10-Q · filed 2018-05-08 | |
| 2017-12-31 | $321.90M 10-K · filed 2019-02-27 | |
| 2017-09-30 | $357.70M 10-Q · filed 2017-11-09 | |
| 2017-07-01 | $368.40M 10-Q · filed 2017-08-10 | |
| 2017-04-01 | $349.40M 10-Q · filed 2017-05-30 | |
| 2016-12-31 | $389.90M 10-K · filed 2018-03-01 | |
| 2015-12-31 | $1.37B 10-K · filed 2018-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |